South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Freenome is raising $300,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Nolan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Freenome
Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.

To learn more about Freenome, visit http://www.freenome.com/

Contact:
Michael Nolan, Chief Executive Officer
831-704-6883
https://www.linkedin.com/in/mike-nolan-6b41b041/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved